Measles immunity after allogeneic stem cell transplantation; influence of donor type, graft type, intensity of conditioning, and graft-versus host disease

Bone Marrow Transplantation

Volumn 34, Issue 7, 2004, Pages 589-593

  Ljungman, Per ^a   Aschan, J ^a   Barkholt, L ^a   Broliden, P A ^a   Gustafsson, B ^a   Lewensohn Fuchs, I ^a   Lofgren C ^a   Winiarski, J ^a   Ringden O ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Immunity; Measles; Risk factors

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; MEASLES VACCINE; METHOTREXATE;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHILD; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; DISEASE SEVERITY; FAMILY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MEASLES; MEASLES VACCINATION; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SEROLOGY; SIBLING;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MEASLES; MEASLES VACCINE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 5044242799     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704634     Document Type: Article

References (24)

1. Ljungman P, Lewensohn-Fuchs I, Hammarstrom V et al. Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantation. Blood 1994; 84 (2): 657-663.
2. Machado CM, Goncalves FB, Pannuti CS et al. Measles in bone marrow transplant recipients during an outbreak in Sao Paulo, Brazil. Blood 2002; 99 (1): 83-87.
3. Nakano T, Shimono Y, Sugiyama K et al. Clinical features of measles in immunocompromised children. Acta Paediatr Jpn 1996; 38 (3): 212-217.
4. Kaplan L, Daum R, Smaron M, McCarthy C. Severe measles in immunocompromised patients. JAMA 1992; 267 (9): 1237-1241.
5. Ringden O, Remberger M, Carlens S et al. Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies. Transplantation 1998; 66 (5): 620-625.
6. Ringdén O, Remberger M, Persson U et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995; 15 (4): 619 625.
7. Ringdén O, Pihlstedt P, Markling L et al. Prevention of graft-versus-host disease with T-cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991; 7: 221-226.
8. Ljungman P, Fridell E, Lönnqvist B et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis 1989; 159 (4): 610-615.
9. Ljungman P. Immunization of transplant recipients. Bone Marrow Transplant 1999; 23 (7): 635-636.
10. Remberger M, Kumlien G, Aschan J et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8 (12): 674-682.
11. Ringden O, Labopin M, Bacigalupo A et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 2002; 20 (24): 4655-4664.
12. Ringden O, Remberger M, Runde V et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood 1999; 94 (2): 455-464.
13. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97 (11): 3390-3400.
14. Update: global measles control and mortality reduction - worldwide. 1991-2001. MMWR Morb Mortal Wkly Rep 2003; 52 (20): 471-475.
15. Maris M, Boeckh M, Storer B et al. Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Exp Hematol 2003; 31 (10): 941-952.
16. D'Sa S, Peggs K, Pizzey A et al. T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions. Br J Haematol 2003; 123 (2): 309-322.
17. Kanra G, Cetin I, Akcoren Z et al. Giant cell pneumonia in a leukemic child in remission: a case report. Turk J Pediatr 2001; 43 (4): 338-341.
18. Haltia M, Paetau A, Vaheri A et al. Fatal measles encephalopathy with retinopathy during cytotoxic chemotherapy. J Neurol Sci 1977; 32 (3): 323-330.
19. Breitfeld V, Hashida Y, Sherman F et al. Fatal measles infection in children with leukemia. Lab Invest 1973; 29: 279-281.
20. Measles epidemic attributed to inadequate vaccination coverage - Campania, Italy. 2002. MMWR - Morb Mortal Wkly Rep 2003; 53 (43): 1044-1047.
21. Nakajima N, Matsuda T, Ono T et al. Measles outbreak in a suburb of Tokyo, Japan, in 1998-1999. Scand J Infect Dis 2003; 35 (8): 495-497.
22. McBrien J, Murphy J, Gill D et al. Measles outbreak in Dublin, 2000. Pediatr Infect Dis J 2003; 22 (7): 580-584.
23. Anonymous. Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection. MMWR - Morb Mort Weekly Rep 1996; 45 (28): 603-606.
24. CDC. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR - Morb Mortal Wkly Rep 2000; 49 (RR-10): 1-125.